Us Bancorp \De\ Zentalis Pharmaceuticals, Inc. Transaction History

Us Bancorp \De\

$78.3 Billion
Q2 2025

A detailed history of Us Bancorp \De\ transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 1,164 shares of ZNTL stock, worth $1,641. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,164

Previous 9,299 87.48%

Holding current value

$1,641

Previous $14,000 92.86%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 23, 2025	SELL	$1.04 - $1.63 $8,460 - $13,260	-8,135 Reduced 87.48%	1,164 $1,000
Q1 2025 May 08, 2025	BUY	$1.59 - $3.24 $14,785 - $30,128	9,299 New	9,299 $14,000
Q3 2024 Oct 28, 2024	SELL	$2.9 - $4.57 $1,815 - $2,860	-626 Reduced 62.04%	383 $1,000
Q2 2024 Aug 06, 2024	BUY	$4.09 - $16.13 $1,468 - $5,790	359 Added 55.23%	1,009 $4,000
Q1 2024 May 07, 2024	SELL	$10.83 - $16.49 $86 - $131	-8 Reduced 1.22%	650 $10,000
Q4 2023 Feb 09, 2024	SELL	$9.84 - $20.13 $2,253 - $4,609	-229 Reduced 25.82%	658 $9,000
Q2 2023 Aug 09, 2023	BUY	$17.41 - $30.05 $7,259 - $12,530	417 Added 88.72%	887 $25,000
Q1 2023 May 09, 2023	BUY	$16.14 - $24.94 $7,133 - $11,023	442 Added 1578.57%	470 $8,000
Q3 2022 Oct 27, 2022	SELL	$20.23 - $31.73 $25,247 - $39,599	-1,248 Reduced 97.81%	28 $1,000
Q2 2022 Aug 01, 2022	SELL	$17.91 - $52.25 $3,134 - $9,143	-175 Reduced 12.06%	1,276 $36,000
Q1 2022 May 11, 2022	BUY	$41.58 - $80.89 $47,733 - $92,861	1,148 Added 378.88%	1,451 $67,000
Q4 2021 Feb 11, 2022	BUY	$66.92 - $84.79 $20,276 - $25,691	303 New	303 $25,000

Others Institutions Holding ZNTL

# of Institutions

127

Shares Held

57.9M

Call Options Held

7.9K

Put Options Held

42.5K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $80.3M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account